Pricing Disclosure Demands During Medicare Negotiation Process May Be Fodder For Lawsuits
Executive Summary
Regulatory attorneys suggest different issues that might form the basis of manufacturer-sponsored litigation against the Centers for Medicare and Medicaid Services.
You may also be interested in...
Merck Files First IRA Suit, Signaling Industry Is Ready To Fight
Coming less than three months before the statutory deadline for CMS to publish the initial list of drugs, Merck’s lawsuit calls US Medicare drug price negotiations ‘extortion’ in a complaint that could be the first of more legal pushback to follow.
Merck & Co. Files First IRA Suit, Signaling Industry Is Ready To Fight
Coming less than three months before the statutory deadline for CMS to publish the initial list of drugs, Merck’s lawsuit calls US Medicare drug price negotiations ‘extortion’ in a complaint that could be the first of more legal pushback to follow.
CMS Official Calls Medicare Price Negotiations An ‘Ongoing Conversation’
The US Centers for Medicare & Medicaid Services’ Vinod Mitta discussed the agency’s latest thinking on the implementation of Medicare drug price negotiations at the Financial Times Pharma Summit.